We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases. Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic. Source
No articles found.
ââOrthofix Medical Inc. is a diversified, global medical device company focuse...
ââOrthofix Medical Inc. is a diversified, g...
Unlimited Tomorrow is here to change the way we think about artificial limbs. They...
Unlimited Tomorrow is here to change the way we...
Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin ...
Sophiris Bio Inc. is a late-stage biopharmaceut...
We make affordable assistive products, starting with a groundbreaking supportive w...
We make affordable assistive products, starting...
Developing flexible and affordable genetic testing that improves the everyday live...
Developing flexible and affordable genetic test...
ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broade...
ENDRA Life Sciences' mission is to bring new ca...
Join the National Investor Network and get the latest information with your interests in mind.